Insulet Corp.

Bedford, Mass. • 781-457-5000 •

Exchange and Ticker: Nasdaq: PODD

Filing Range: 6.70M shares @ $14.00 to $16.00

Offering Price: $15.00

Close on First Day: $15.96

Offering Size: $115.50M

Shares Outstanding: 24,633,237M

Underwriters: JP Morgan/ Merrill Lynch

Co-managers: Thomas Weisel Partners LLC/ Leerink Swann & Co.

Company Counsel: Goodwin Procter LLP

Manager Counsel: Cahill Gordon & Reindel

Auditor: Ernst & Young LLP

Market Capitalization on 5/31/07: $365.06M

Close price at current month end: $14.82


Develops disposable insulin delivery systems for the treatment of diabetes. The company’s patients are able to program the system using a wireless, handheld device. Insulet’s patch can be worn by a patient for three days at a time. Insulet Corp.’s first commercial product, the OmniPod Insulin Management System, has been designed to break down the barriers to CSII therapy and improve health outcomes. Competitors include Medtronic MiniMed, Animas Corp., Deltec, Pfizer Inc, Abbott Laboratories, Eli Lilly and Co., MannKind Corp., Novo Nordisk AS and Takeda Pharmaceuticals Co. Ltd.


Alta Partners, Diamond Capital Co., Kaufmann Fund Inc., MedVenture Associates, Oakwood Medical Investors, OrbiMed Advisors LLC, Pequot Capital Management Inc., Permira Advisers Ltd., Prism Venture Partners, Red Abbey Venture Partners, SightLine Partners, SV Life Sciences Advisers, Teachers Insurance & Annuity Association College Retirement, Versant Ventures.

Source: Thomson Financial